The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as booster dose. Separately, the DCGI also granted permission to the firm to conduct phase-3 clinical trial to compare the immunogenecity and safety of BBV-154 (intranasal) with Covaxin. This trial has been permitted to be conducted at nine sites.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/eYjiOMw
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Bharat Biotech expects regulator's nod for intranasal COVID-19 vaccine in Aug
https://ift.tt/ZyuA3IP
No comments:
Post a Comment